New benefits of the slimming injection Ozempic have emerged. In a study conducted on thousands of people, scientists observed that the injection reduced both kidney and heart-related risks. At the same time, there was a decrease in the risk of death.
Slimming needle also used in diabetes treatment Ozempic Research was being conducted showing that it had significant benefits for human health. For example, a recent study found findings showing that it can reduce the risk of heart attack and stroke. The reason for this is that it helps suppress appetite. semaglutide It was stated that it was a compound named .
Now, another benefit of the injection has been discovered. In a new study, scientists found that Ozempic may be very beneficial to kidney health. The findings were published through the New England Journal of Medicine.
It has been shown to reduce kidney and heart-related risks as well as the risk of death.
3500 people from 28 countries participated in the study. Participants included both type 2 diabetes and chronic kidney disease patients. These people were given small doses of semaglutide, the active ingredient in Ozempic, weekly between June 2019 and May 2021. Nothing was applied to the other half.
After nearly two years, scientists compared the results. It was observed that those who received weekly injections had a lower risk of kidney failure and their body weight decreased compared to the other group. The examinations made after 3.5 years showed that these people kidney related risks 24% was less. Heart-related risks are reduced by 18% It was seen to be. Besides these The risk of death decreases by 20% observed.
Researcher Vlado Perkovic from the University of New South Wales in Australia said:By making this medicine available to them We can save their kidneys, hearts and lives. “This is very unusual for a single treatment.” he said.
RELATED NEWS
“What Should I Do to Lose Weight?” 11 Answers of Science to the Question (Be Prepared to Forget Some of What You Know!)
Of course, it is too early to say definitively that it should be used against these risks. Although scientists are hopeful, testing on more people wants. It is also unclear whether the drug will pose a risk in the long term. In addition, there is not much information about why semaglutide is so useful. Predictions are that it may be due to its direct effect on the kidney or to reduce fat in the body. In short, we need much more work to be done on this subject.